title: Lysophosphatidylcholine- and MCP-1-induced chemotaxis of monocytes requires potassium channel activity.
abstract: One of the earliest cellular responses in atherogenesis is the focal recruitment of circulating monocytes, while the most important atherogenic chemoattractants are monocyte chemoattractant protein-1 (MCP-1) and lysophosphatidylcholine (LPC). Invading monocytes transform into activated macrophages and foam cells, which stimulate inflammatory processes and promote atherosclerosis. In this study, we have searched for common mechanisms involved in MCP-1- and LPC-stimulated monocyte migration. We have found that migration of THP-1 monocytes stimulated with MCP-1 was reduced upon inhibition of G(i/o) proteins with pertussis toxin and upon inhibition of platelet activating factor receptors with BN52021, whereas LPC-stimulated monocyte chemotaxis remained unaffected by both inhibitors. Furthermore, Cl(-) channels were only required for MCP-1-induced chemotaxis. However, activity of voltage-gated K+ channels and of Ca2+-activated K+ channels was found to be involved in migration of monocytes stimulated with either MCP-1 or LPC. Inhibition of voltage-gated K+ channels with 4-aminopyridine or margatoxin partially inhibited MCP-1- and LPC-stimulated migration of monocytes. Blockade of Ca2+-activated K+ channels with TRAM-34 also partially reduced migration of MCP-1- and LPC-stimulated monocytes. Simultaneous inhibition of voltage-gated and Ca2+-activated K+ channels abolished MCP-1- and LPC-induced chemotaxis of monocytes. Thus, K+ channel inhibition may represent a novel powerful strategy to reduce monocyte infiltration and subsequent inflammation in atherosclerosis.
authors.affiliation: Division of Basic Medical Sciences, St. George's University of London, Cranmer Terrace, London, SW17 0RE, UK.
authors.forename: Tom
authors.initials: T
authors.lastname: Schilling
authors.forename: Claudia
authors.initials: C
authors.lastname: Eder
mesh_terms: D050197:Atherosclerosis / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D018932:Chemokine CCL2 / Q000378:metabolism*; D002634:Chemotaxis, Leukocyte / Q000502:physiology*; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008244:Lysophosphatidylcholines / Q000378:metabolism*; D009000:Monocytes / Q000378:metabolism*; D015221:Potassium Channels / Q000378:metabolism*
chemical_list: C111835:CCL2 protein, human; D018932:Chemokine CCL2; D008244:Lysophosphatidylcholines; D015221:Potassium Channels
references.citation: Int J Cardiol. 1997 Dec 31;62 Suppl 2:S85-90
references.pmid: 9488199
references.citation: Pflugers Arch. 1995 Sep;430(5):802-7
references.pmid: 7478936
references.citation: Blood. 2005 Feb 1;105(3):1127-34
references.pmid: 15383458
references.citation: Curr Opin Lipidol. 2001 Apr;12(2):175-80
references.pmid: 11264989
references.citation: Pflugers Arch. 2009 Sep;458(5):981-92
references.pmid: 19437033
references.citation: J Cell Physiol. 2009 Nov;221(2):325-34
references.pmid: 19562685
references.citation: Arterioscler Thromb Vasc Biol. 2002 Dec 1;22(12):2049-53
references.pmid: 12482833
references.citation: Annu Rev Pathol. 2006;1:297-329
references.pmid: 18039117
references.citation: J Clin Invest. 1997 Nov 15;100(10):2552-61
references.pmid: 9366570
references.citation: J Cell Physiol. 2006 Jan;206(1):86-94
references.pmid: 15965951
references.citation: J Clin Invest. 2008 Sep;118(9):3025-37
references.pmid: 18688283
references.citation: J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C7-12
references.pmid: 16631513
references.citation: Curr Med Chem. 2007;14(30):3209-20
references.pmid: 18220755
references.citation: J Membr Biol. 1996 Jul;152(2):141-57
references.pmid: 9139125
references.citation: Nature. 1998 Aug 27;394(6696):894-7
references.pmid: 9732872
references.citation: Nat Rev Immunol. 2006 Jul;6(7):508-19
references.pmid: 16778830
references.citation: Pflugers Arch. 2007 Jul;454(4):559-63
references.pmid: 17318643
references.citation: Nat Struct Biol. 2002 Sep;9(9):696-703
references.pmid: 12172537
references.citation: Clin Exp Immunol. 2004 Dec;138(3):453-9
references.pmid: 15544622
references.citation: Pflugers Arch. 2007 Jan;453(4):421-32
references.pmid: 17021798
references.citation: Am J Physiol. 1997 Jan;272(1 Pt 2):H17-24
references.pmid: 9038918
references.citation: J Membr Biol. 1996 Jul;152(2):117-30
references.pmid: 9139123
references.citation: Proc Natl Acad Sci U S A. 1988 Apr;85(8):2805-9
references.pmid: 3357891
references.citation: J Rehabil Res Dev. 2006 Jan-Feb;43(1):111-22
references.pmid: 16847777
references.citation: J Lipid Res. 2005 Jul;46(7):1405-15
references.pmid: 15834123
references.citation: BioDrugs. 2004;18(5):329-41
references.pmid: 15377175
references.citation: J Lipid Res. 1999 Jun;40(6):988-93
references.pmid: 10357830
references.citation: J Physiol. 2004 May 15;557(Pt 1):105-20
references.pmid: 15020687
references.citation: Physiol Rev. 2003 Oct;83(4):1069-112
references.pmid: 14506301